Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

FDA Grants Orphan Drug Status to Amatuximab for Malignant Pleural Mesothelioma

November 12th 2012

Amatuximab has received orphan drug status from the FDA to treat patients with malignant pleural mesothelioma, the most common form of mesothelioma.

Dr. Kris Discusses Crizotinib in ALK-Positive Lung Cancer

November 2nd 2012

Mark G. Kris, MD, from Memorial Sloan-Kettering Cancer Center, discusses the results of a phase III trial that studied the use of crizotinib in patients with advanced ALK-positive lung cancer.

No Survival Benefit Found When Adding Bevacizumab to Gemcitabine/Cisplatin in Malignant Mesothelioma

October 31st 2012

The addition of bevacizumab to gemcitabine/cisplatin does not significantly improve progression-free survival or overall survival in patients with previously untreated, unresectable malignant mesothelioma.

Dr. Gandara Describes Exciting Lung Cancer Research

October 24th 2012

David R. Gandara, MD, University of California, Davis Comprehensive Cancer Center, provides his opinion on some of the most exciting research currently taking place for patients with NSCLC.

Dacomitinib Bests Erlotinib in Advanced Non-Small Cell Lung Cancer

October 23rd 2012

Treatment with the investigational agent dacomitinib improved PFS when compared with erlotinib in patients with non–small cell lung cancer experiencing progression during chemotherapy.

7th New York Lung Cancer Symposium Provides Overview

October 22nd 2012

Targeted therapies, personalized medicine, and best management approaches will be the central topics of discussion at the 7th New York Lung Cancer Symposium.

Tackling Questions on Genetic Testing

October 19th 2012

The expansion of testing for genetic abnormalities in patients with advanced lung cancer is generating questions about which patients' tumors should be tested, how they should be tested, and whether they should be retested.

Dr. Langer on Targeted Agents for Locally Advanced NSCLC

October 19th 2012

Corey J. Langer, MD, from the Abramson Cancer Center, discusses the investigation of targeted therapies for patients with locally advanced non-small cell lung cancer.

Evolving Biologic Diversity Generates New Challenges

October 16th 2012

The heterogeneity of lung tumors generates challenges in terms of the costs and logistics of developing targeted therapies, given that relatively few patients may harbor a particular mutation.

FDA Approves Nab-Paclitaxel for Advanced Lung Cancer

October 12th 2012

The FDA has approved nab-paclitaxel plus carboplatin for patients with untreated locally advanced or metastatic NSCLC who are not candidates for surgery or radiation.

CT Screening Evolves Amid Questions and Controversy

October 10th 2012

Nearly 2 years after a landmark study supported CT for people at high risk of developing lung cancer, questions persist about the complexities of implementing an early detection program.

No Survival Benefit With Add-On Sorafenib in Advanced Lung Cancer

October 9th 2012

The addition of sorafenib to first-line gemcitabine/cisplatin does not appear to lengthen survival in patients with advanced, nonsquamous, non–small cell lung cancer.

From Survivor to Advocate: How One Patient Launched Two Foundations

October 5th 2012

As Bonnie Addario has gone from patient to survivor, she has learned much about what patients are looking for in terms of information and care.

Molecular Discoveries Pave Way for Rapid Advances in Lung Cancer

October 5th 2012

An interview with Giorgio V. Scagliotti, MD, who has played a prominent role in researching and developing therapies to attack molecular targets.

Tivantinib Study Halted Following Interim Analysis

October 3rd 2012

The phase III MARQUEE trial examining tivantinib has been halted following a planned interim analysis because it was not expected to meet its primary endpoint.

Positive Results in ALK-Positive NSCLC With First ALK Inhibitor

October 1st 2012

Crizotinib extended PFS and improved response rates compared with single-agent chemotherapy with pemetrexed or docetaxel in patients with advanced, previously treated, ALK-positive, NSCLC.

Bonnie Addario Discusses the Stigma of Lung Cancer

September 19th 2012

Lung cancer survivor, Bonnie Addario, the founder of the Bonnie J. Addario Lung Cancer Foundation, discusses the prevalent stigma that lung cancer is a self-inflicted disease caused solely by smoking.

Dr. Spigel Discusses the Evolving NSCLC Treatment Landscape

September 14th 2012

Dr. David Spigel, from the Sarah Cannon Research Institute, discusses the rapidly evolving non-small cell lung cancer treatment landscape.

Dr. Reckamp Evaluates the Predictive Efficacy of VeriStrat

September 14th 2012

Dr. Karen Reckamp, from City of Hope, evaluates the predictive efficacy of the pretreatment serum test VeriStrat for non-small cell lung cancer.

Targeted Therapy Combination Slows NSCLC

September 14th 2012

Patients with refractory non-small cell lung cancer had a statistically significant improvement in PFS when treated with targeted therapy duo versus a single agent.

NEXT PAGE
PREVIOUS PAGE